{"id":16477,"date":"2026-05-26T15:07:56","date_gmt":"2026-05-26T13:07:56","guid":{"rendered":"https:\/\/www.interpharma.ch\/?p=16477"},"modified":"2026-05-26T15:07:57","modified_gmt":"2026-05-26T13:07:57","slug":"3-questions-a-notre-nouveau-membre-du-conseil-dadministration-jerome-garcin-general-manager-for-switzerland-and-austria-bristol-myers-squibb","status":"publish","type":"post","link":"https:\/\/www.interpharma.ch\/fr\/blog\/3-questions-a-notre-nouveau-membre-du-conseil-dadministration-jerome-garcin-general-manager-for-switzerland-and-austria-bristol-myers-squibb\/","title":{"rendered":"3 questions \u00e0 notre nouveau membre du conseil d\u2019administration: J\u00e9rome Garcin, General Manager for Switzerland and Austria, Bristol Myers Squibb"},"content":{"rendered":"\n<figure class=\"wp-block-image size-large\"><img loading=\"lazy\" decoding=\"async\" width=\"1575\" height=\"1181\" src=\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/05\/Jerome_Garcin_\u00a9-BMS-Switzerland-edited.jpg\" alt=\"Ein Bild von J\u00e9rome Garcin, General Manager for Switzerland and Austria bei Bristol Myers Squibb und Boardmitglied von Interpharma\" class=\"wp-image-16474\" srcset=\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/05\/Jerome_Garcin_\u00a9-BMS-Switzerland-edited.jpg 1575w, https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/05\/Jerome_Garcin_\u00a9-BMS-Switzerland-edited-800x600.jpg 800w, https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/05\/Jerome_Garcin_\u00a9-BMS-Switzerland-edited-1200x900.jpg 1200w, https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/05\/Jerome_Garcin_\u00a9-BMS-Switzerland-edited-768x576.jpg 768w, https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/05\/Jerome_Garcin_\u00a9-BMS-Switzerland-edited-1536x1152.jpg 1536w\" sizes=\"auto, (max-width: 1575px) 100vw, 1575px\" \/><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-vous-avez-accumule-beaucoup-d-experience-dans-differents-pays-comment-evaluez-vous-la-situation-de-l-industrie-pharmaceutique-en-suisse\"><strong><strong>Vous avez accumul\u00e9 beaucoup d\u2019exp\u00e9rience dans diff\u00e9rents pays. Comment \u00e9valuez-vous la situation de l\u2019industrie pharmaceutique en Suisse?<\/strong><\/strong><\/h2>\n\n\n\n<p>La Suisse est consid\u00e9r\u00e9e \u00e0 juste titre comme l\u2019une des places mondialement en pointe pour les sciences de la vie. La combinaison d\u2019excellence scientifique, d\u2019un \u00e9cosyst\u00e8me d\u2019innovation puissant et d\u2019un syst\u00e8me de sant\u00e9 de haute qualit\u00e9 est unique en son genre. Du point de vue des march\u00e9s internationaux, je pense que cette r\u00e9putation est absolument justifi\u00e9e, mais aussi qu\u2019elle est soumise \u00e0 une pression croissante.<\/p>\n\n\n\n<p>Depuis quelques ann\u00e9es, l\u2019acc\u00e8s des patientes et patients aux traitements innovants s\u2019est d\u00e9grad\u00e9 et la disponibilit\u00e9 des nouveaux m\u00e9dicaments est moins bonne que dans des pays comparables. Des retards dans le syst\u00e8me de remboursement et une focalisation croissante sur des \u00e9conomies \u00e0 court terme font que le syst\u00e8me a du mal \u00e0 suivre le rythme du progr\u00e8s scientifique. En m\u00eame temps, la concurrence mondiale pour les investissements et les priorit\u00e9s de mise sur le march\u00e9 s\u2019accentue et de nouvelles dynamiques des prix ont une influence sur les pays o\u00f9 les entreprises d\u00e9cident de mettre leurs innovations sur le march\u00e9 en premier.<\/p>\n\n\n\n<p>La Suisse se trouve \u00e0 un tournant important. Les d\u00e9cisions prises actuellement en mati\u00e8re d\u2019acc\u00e8s, de pr\u00e9visibilit\u00e9 et d\u2019attrait g\u00e9n\u00e9ral de la place suisse seront capitales pour que le pays puisse conserver sa place de leader et que les patientes et patients b\u00e9n\u00e9ficient encore \u00e0 l\u2019avenir d\u2019un acc\u00e8s rapide aux m\u00e9dicaments et traitements innovants.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-ou-voyez-vous-les-principaux-points-forts-de-la-suisse-en-comparaison-internationale\"><strong><strong>O\u00f9 voyez-vous les principaux points forts de la Suisse en comparaison internationale?<\/strong><\/strong><\/h2>\n\n\n\n<p>Le principal point fort de la Suisse est son \u00e9cosyst\u00e8me des sciences de la vie extr\u00eamement bien connect\u00e9. Rares sont les pays qui r\u00e9unissent de mani\u00e8re aussi bien int\u00e9gr\u00e9e et qui se renforce mutuellement des universit\u00e9s de premier ordre, des institutions de sant\u00e9 de pointe et une industrie pharmaceutique et biotechnologique hautement innovante. Cela cr\u00e9e un environnement qui aide \u00e0 ce que les progr\u00e8s scientifiques passent rapidement de la d\u00e9couverte \u00e0 l\u2019application pratique.<\/p>\n\n\n\n<p>\u00c0 l\u2019\u00e9chelon international, la Suisse se distingue par sa place in\u00e9branlable de leader au niveau des chiffres cl\u00e9s de l\u2019innovation, dont une position de pointe dans le nombre de brevets par habitant dans le secteur des sciences de la vie. En m\u00eame temps, le pays b\u00e9n\u00e9ficie de son syst\u00e8me de sant\u00e9 performant, bas\u00e9 sur la solidarit\u00e9, un large acc\u00e8s et une grande confiance de la soci\u00e9t\u00e9 dans la science, avantage qui ne va pas de soi dans de nombreux autres march\u00e9s.<\/p>\n\n\n\n<p>Cette combinaison d\u2019excellence scientifique, de performance du syst\u00e8me et de confiance de la soci\u00e9t\u00e9 fait de la Suisse une place tout particuli\u00e8rement attrayante pour la recherche, le d\u00e9veloppement et la mise \u00e0 disposition d\u2019une prise en charge de haut niveau pour les patientes et patients.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-en-tant-que-membre-nouvellement-elu-au-comite-directeur-d-interpharma-vous-allez-a-present-pouvoir-mettre-votre-experience-internationale-au-service-de-l-industrie-pharmaceutique-suisse-quelles-seront-vos-priorites\"><strong><strong>En tant que membre nouvellement \u00e9lu au comit\u00e9 directeur d\u2019Interpharma, vous allez \u00e0 pr\u00e9sent pouvoir mettre votre exp\u00e9rience internationale au service de l\u2019industrie pharmaceutique suisse. Quelles seront vos priorit\u00e9s?<\/strong><\/strong><\/h2>\n\n\n\n<p>Ma priorit\u00e9 est de contribuer \u00e0 ce que la Suisse reste \u00e0 l\u2019avenir une place leader dans le domaine des sciences de la vie et que les patientes et patients aient en m\u00eame temps rapidement acc\u00e8s aux traitements innovants, ceci gr\u00e2ce \u00e0 des r\u00e8glementations qui r\u00e9tribuent l\u2019innovation scientifique de mani\u00e8re ad\u00e9quate. Ces deux questions sont intimement li\u00e9es: un \u00e9cosyst\u00e8me d\u2019innovation puissant ne peut d\u00e9ployer pleinement ses avantages que si les patientes et patients b\u00e9n\u00e9ficient des nouveaux traitements sans retards inutiles.<\/p>\n\n\n\n<p>Pour y arriver, il faut des conditions cadres stables et pr\u00e9visibles qui soutiennent les investissements \u00e0 long terme, favorisent le progr\u00e8s scientifique et maintiennent la comp\u00e9titivit\u00e9 mondiale de la Suisse. Cela requiert une \u00e9troite coop\u00e9ration entre la politique, le syst\u00e8me de sant\u00e9 et l\u2019industrie pour d\u00e9velopper des approches de solution durables et orient\u00e9es vers l\u2019avenir. <\/p>\n\n\n\n<p>Dans ce contexte, je pense que mon r\u00f4le est d\u2019allier d\u00e9termination et travail en partenariat, de d\u00e9finir des objectifs clairs pour l\u2019avenir et de coop\u00e9rer en m\u00eame temps de mani\u00e8re constructive avec toutes les parties prenantes pour les atteindre.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>J\u00e9rome Garcin, General Manager for Switzerland and Austria bei Bristol Myers Squibb und Boardmitglied von Interpharma<\/p>\n","protected":false},"author":8,"featured_media":16478,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"tags":[127,130,182,120],"class_list":["post-16477","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","tag-acces-des-patients","tag-pharmastandort-2030-fr","tag-forschung","tag-innovation-fr"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.2 (Yoast SEO v27.2) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>3 questions \u00e0 notre nouveau membre du conseil d\u2019administration: J\u00e9rome Garcin, General Manager for Switzerland and Austria, Bristol Myers Squibb - Interpharma<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.interpharma.ch\/fr\/blog\/3-questions-a-notre-nouveau-membre-du-conseil-dadministration-jerome-garcin-general-manager-for-switzerland-and-austria-bristol-myers-squibb\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"3 questions \u00e0 notre nouveau membre du conseil d\u2019administration: J\u00e9rome Garcin, General Manager for Switzerland and Austria, Bristol Myers Squibb\" \/>\n<meta property=\"og:description\" content=\"J\u00e9rome Garcin, General Manager for Switzerland and Austria bei Bristol Myers Squibb und Boardmitglied von Interpharma\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.interpharma.ch\/fr\/blog\/3-questions-a-notre-nouveau-membre-du-conseil-dadministration-jerome-garcin-general-manager-for-switzerland-and-austria-bristol-myers-squibb\/\" \/>\n<meta property=\"og:site_name\" content=\"Interpharma\" \/>\n<meta property=\"article:published_time\" content=\"2026-05-26T13:07:56+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-05-26T13:07:57+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/05\/Jerome_Garcin_\u00a9-BMS-Switzerland.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1575\" \/>\n\t<meta property=\"og:image:height\" content=\"2362\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"georgdaerendinger\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@interpharma_ch\" \/>\n<meta name=\"twitter:site\" content=\"@interpharma_ch\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"georgdaerendinger\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/3-questions-a-notre-nouveau-membre-du-conseil-dadministration-jerome-garcin-general-manager-for-switzerland-and-austria-bristol-myers-squibb\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/3-questions-a-notre-nouveau-membre-du-conseil-dadministration-jerome-garcin-general-manager-for-switzerland-and-austria-bristol-myers-squibb\/\"},\"author\":{\"name\":\"georgdaerendinger\",\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/person\/084d5698c6a33caa3c77f9b64b2e4359\"},\"headline\":\"3 questions \u00e0 notre nouveau membre du conseil d\u2019administration: J\u00e9rome Garcin, General Manager for Switzerland and Austria, Bristol Myers Squibb\",\"datePublished\":\"2026-05-26T13:07:56+00:00\",\"dateModified\":\"2026-05-26T13:07:57+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/3-questions-a-notre-nouveau-membre-du-conseil-dadministration-jerome-garcin-general-manager-for-switzerland-and-austria-bristol-myers-squibb\/\"},\"wordCount\":765,\"publisher\":{\"@id\":\"https:\/\/www.interpharma.ch\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/3-questions-a-notre-nouveau-membre-du-conseil-dadministration-jerome-garcin-general-manager-for-switzerland-and-austria-bristol-myers-squibb\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/05\/Jerome_Garcin_\u00a9-BMS-Switzerland.jpg\",\"keywords\":[\"Acc\u00e8s des patients\",\"Pharmastandort 2030\",\"Forschung\",\"Innovation\"],\"inLanguage\":\"fr-FR\",\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\/\/www.interpharma.ch\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/3-questions-a-notre-nouveau-membre-du-conseil-dadministration-jerome-garcin-general-manager-for-switzerland-and-austria-bristol-myers-squibb\/\",\"url\":\"https:\/\/www.interpharma.ch\/fr\/blog\/3-questions-a-notre-nouveau-membre-du-conseil-dadministration-jerome-garcin-general-manager-for-switzerland-and-austria-bristol-myers-squibb\/\",\"name\":\"3 questions \u00e0 notre nouveau membre du conseil d\u2019administration: J\u00e9rome Garcin, General Manager for Switzerland and Austria, Bristol Myers Squibb - Interpharma\",\"isPartOf\":{\"@id\":\"https:\/\/www.interpharma.ch\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/3-questions-a-notre-nouveau-membre-du-conseil-dadministration-jerome-garcin-general-manager-for-switzerland-and-austria-bristol-myers-squibb\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/3-questions-a-notre-nouveau-membre-du-conseil-dadministration-jerome-garcin-general-manager-for-switzerland-and-austria-bristol-myers-squibb\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/05\/Jerome_Garcin_\u00a9-BMS-Switzerland.jpg\",\"datePublished\":\"2026-05-26T13:07:56+00:00\",\"dateModified\":\"2026-05-26T13:07:57+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/3-questions-a-notre-nouveau-membre-du-conseil-dadministration-jerome-garcin-general-manager-for-switzerland-and-austria-bristol-myers-squibb\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.interpharma.ch\/fr\/blog\/3-questions-a-notre-nouveau-membre-du-conseil-dadministration-jerome-garcin-general-manager-for-switzerland-and-austria-bristol-myers-squibb\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/3-questions-a-notre-nouveau-membre-du-conseil-dadministration-jerome-garcin-general-manager-for-switzerland-and-austria-bristol-myers-squibb\/#primaryimage\",\"url\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/05\/Jerome_Garcin_\u00a9-BMS-Switzerland.jpg\",\"contentUrl\":\"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/05\/Jerome_Garcin_\u00a9-BMS-Switzerland.jpg\",\"width\":1575,\"height\":2362,\"caption\":\"Ein Bild von J\u00e9rome Garcin, General Manager for Switzerland and Austria bei Bristol Myers Squibb und Boardmitglied von Interpharma\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.interpharma.ch\/fr\/blog\/3-questions-a-notre-nouveau-membre-du-conseil-dadministration-jerome-garcin-general-manager-for-switzerland-and-austria-bristol-myers-squibb\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\/\/www.interpharma.ch\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"3 questions \u00e0 notre nouveau membre du conseil d\u2019administration: J\u00e9rome Garcin, General Manager for Switzerland and Austria, Bristol Myers Squibb\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.interpharma.ch\/#website\",\"url\":\"https:\/\/www.interpharma.ch\/\",\"name\":\"Interpharma\",\"description\":\"Verband der forschenden Pharmazeutischen Firmen\",\"publisher\":{\"@id\":\"https:\/\/www.interpharma.ch\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.interpharma.ch\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.interpharma.ch\/#organization\",\"name\":\"Interpharma\",\"url\":\"https:\/\/www.interpharma.ch\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg\",\"contentUrl\":\"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg\",\"width\":\"1200\",\"height\":\"1200\",\"caption\":\"Interpharma\"},\"image\":{\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/x.com\/interpharma_ch\",\"https:\/\/ch.linkedin.com\/company\/interpharma\",\"https:\/\/www.instagram.com\/interpharma_ch\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.interpharma.ch\/#\/schema\/person\/084d5698c6a33caa3c77f9b64b2e4359\",\"name\":\"georgdaerendinger\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/secure.gravatar.com\/avatar\/7b67b272bf898559e776bf58c8a4a86c1f9be764987cc2813038ee48b29235d1?s=96&d=mm&r=g\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/7b67b272bf898559e776bf58c8a4a86c1f9be764987cc2813038ee48b29235d1?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/7b67b272bf898559e776bf58c8a4a86c1f9be764987cc2813038ee48b29235d1?s=96&d=mm&r=g\",\"caption\":\"georgdaerendinger\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"3 questions \u00e0 notre nouveau membre du conseil d\u2019administration: J\u00e9rome Garcin, General Manager for Switzerland and Austria, Bristol Myers Squibb - Interpharma","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.interpharma.ch\/fr\/blog\/3-questions-a-notre-nouveau-membre-du-conseil-dadministration-jerome-garcin-general-manager-for-switzerland-and-austria-bristol-myers-squibb\/","og_locale":"fr_FR","og_type":"article","og_title":"3 questions \u00e0 notre nouveau membre du conseil d\u2019administration: J\u00e9rome Garcin, General Manager for Switzerland and Austria, Bristol Myers Squibb","og_description":"J\u00e9rome Garcin, General Manager for Switzerland and Austria bei Bristol Myers Squibb und Boardmitglied von Interpharma","og_url":"https:\/\/www.interpharma.ch\/fr\/blog\/3-questions-a-notre-nouveau-membre-du-conseil-dadministration-jerome-garcin-general-manager-for-switzerland-and-austria-bristol-myers-squibb\/","og_site_name":"Interpharma","article_published_time":"2026-05-26T13:07:56+00:00","article_modified_time":"2026-05-26T13:07:57+00:00","og_image":[{"width":1575,"height":2362,"url":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/05\/Jerome_Garcin_\u00a9-BMS-Switzerland.jpg","type":"image\/jpeg"}],"author":"georgdaerendinger","twitter_card":"summary_large_image","twitter_creator":"@interpharma_ch","twitter_site":"@interpharma_ch","twitter_misc":{"\u00c9crit par":"georgdaerendinger","Dur\u00e9e de lecture estim\u00e9e":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/3-questions-a-notre-nouveau-membre-du-conseil-dadministration-jerome-garcin-general-manager-for-switzerland-and-austria-bristol-myers-squibb\/#article","isPartOf":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/3-questions-a-notre-nouveau-membre-du-conseil-dadministration-jerome-garcin-general-manager-for-switzerland-and-austria-bristol-myers-squibb\/"},"author":{"name":"georgdaerendinger","@id":"https:\/\/www.interpharma.ch\/#\/schema\/person\/084d5698c6a33caa3c77f9b64b2e4359"},"headline":"3 questions \u00e0 notre nouveau membre du conseil d\u2019administration: J\u00e9rome Garcin, General Manager for Switzerland and Austria, Bristol Myers Squibb","datePublished":"2026-05-26T13:07:56+00:00","dateModified":"2026-05-26T13:07:57+00:00","mainEntityOfPage":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/3-questions-a-notre-nouveau-membre-du-conseil-dadministration-jerome-garcin-general-manager-for-switzerland-and-austria-bristol-myers-squibb\/"},"wordCount":765,"publisher":{"@id":"https:\/\/www.interpharma.ch\/#organization"},"image":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/3-questions-a-notre-nouveau-membre-du-conseil-dadministration-jerome-garcin-general-manager-for-switzerland-and-austria-bristol-myers-squibb\/#primaryimage"},"thumbnailUrl":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/05\/Jerome_Garcin_\u00a9-BMS-Switzerland.jpg","keywords":["Acc\u00e8s des patients","Pharmastandort 2030","Forschung","Innovation"],"inLanguage":"fr-FR","copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/www.interpharma.ch\/#organization"}},{"@type":"WebPage","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/3-questions-a-notre-nouveau-membre-du-conseil-dadministration-jerome-garcin-general-manager-for-switzerland-and-austria-bristol-myers-squibb\/","url":"https:\/\/www.interpharma.ch\/fr\/blog\/3-questions-a-notre-nouveau-membre-du-conseil-dadministration-jerome-garcin-general-manager-for-switzerland-and-austria-bristol-myers-squibb\/","name":"3 questions \u00e0 notre nouveau membre du conseil d\u2019administration: J\u00e9rome Garcin, General Manager for Switzerland and Austria, Bristol Myers Squibb - Interpharma","isPartOf":{"@id":"https:\/\/www.interpharma.ch\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/3-questions-a-notre-nouveau-membre-du-conseil-dadministration-jerome-garcin-general-manager-for-switzerland-and-austria-bristol-myers-squibb\/#primaryimage"},"image":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/3-questions-a-notre-nouveau-membre-du-conseil-dadministration-jerome-garcin-general-manager-for-switzerland-and-austria-bristol-myers-squibb\/#primaryimage"},"thumbnailUrl":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/05\/Jerome_Garcin_\u00a9-BMS-Switzerland.jpg","datePublished":"2026-05-26T13:07:56+00:00","dateModified":"2026-05-26T13:07:57+00:00","breadcrumb":{"@id":"https:\/\/www.interpharma.ch\/fr\/blog\/3-questions-a-notre-nouveau-membre-du-conseil-dadministration-jerome-garcin-general-manager-for-switzerland-and-austria-bristol-myers-squibb\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.interpharma.ch\/fr\/blog\/3-questions-a-notre-nouveau-membre-du-conseil-dadministration-jerome-garcin-general-manager-for-switzerland-and-austria-bristol-myers-squibb\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/3-questions-a-notre-nouveau-membre-du-conseil-dadministration-jerome-garcin-general-manager-for-switzerland-and-austria-bristol-myers-squibb\/#primaryimage","url":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/05\/Jerome_Garcin_\u00a9-BMS-Switzerland.jpg","contentUrl":"https:\/\/www.interpharma.ch\/wp-content\/uploads\/2026\/05\/Jerome_Garcin_\u00a9-BMS-Switzerland.jpg","width":1575,"height":2362,"caption":"Ein Bild von J\u00e9rome Garcin, General Manager for Switzerland and Austria bei Bristol Myers Squibb und Boardmitglied von Interpharma"},{"@type":"BreadcrumbList","@id":"https:\/\/www.interpharma.ch\/fr\/blog\/3-questions-a-notre-nouveau-membre-du-conseil-dadministration-jerome-garcin-general-manager-for-switzerland-and-austria-bristol-myers-squibb\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/www.interpharma.ch\/fr\/"},{"@type":"ListItem","position":2,"name":"3 questions \u00e0 notre nouveau membre du conseil d\u2019administration: J\u00e9rome Garcin, General Manager for Switzerland and Austria, Bristol Myers Squibb"}]},{"@type":"WebSite","@id":"https:\/\/www.interpharma.ch\/#website","url":"https:\/\/www.interpharma.ch\/","name":"Interpharma","description":"Verband der forschenden Pharmazeutischen Firmen","publisher":{"@id":"https:\/\/www.interpharma.ch\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.interpharma.ch\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.interpharma.ch\/#organization","name":"Interpharma","url":"https:\/\/www.interpharma.ch\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/","url":"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg","contentUrl":"https:\/\/interpharma.ch\/wp-content\/uploads\/2026\/03\/20251014_iph_logo_wort_bildmarke_rgb_final_cu01.svg","width":"1200","height":"1200","caption":"Interpharma"},"image":{"@id":"https:\/\/www.interpharma.ch\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/interpharma_ch","https:\/\/ch.linkedin.com\/company\/interpharma","https:\/\/www.instagram.com\/interpharma_ch\/"]},{"@type":"Person","@id":"https:\/\/www.interpharma.ch\/#\/schema\/person\/084d5698c6a33caa3c77f9b64b2e4359","name":"georgdaerendinger","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/secure.gravatar.com\/avatar\/7b67b272bf898559e776bf58c8a4a86c1f9be764987cc2813038ee48b29235d1?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/7b67b272bf898559e776bf58c8a4a86c1f9be764987cc2813038ee48b29235d1?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/7b67b272bf898559e776bf58c8a4a86c1f9be764987cc2813038ee48b29235d1?s=96&d=mm&r=g","caption":"georgdaerendinger"}}]}},"_links":{"self":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts\/16477","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/users\/8"}],"replies":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/comments?post=16477"}],"version-history":[{"count":3,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts\/16477\/revisions"}],"predecessor-version":[{"id":16524,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/posts\/16477\/revisions\/16524"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/media\/16478"}],"wp:attachment":[{"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/media?parent=16477"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.interpharma.ch\/fr\/wp-json\/wp\/v2\/tags?post=16477"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}